NSE: POLYMED | BSE: 531768

Expensive Underperformer

Download real time

1768.10 25.60 (1.47%)

New 52W Low in past week

53,867 NSE+BSE Volume

NSE 02 Jan, 2026 2:37 PM (IST)

17,921.4

Market Cap

Market Leader

Beta 1Year

Average volatility

Poly Medicure Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for POLYMED, BSE:531768 Poly Medicure Ltd.

Search Inside the pdf :

Poly Medicure Ltd.

27 Dec 2024

1768.10

1.47%

POLY MEDICURE LIMITED

Buy: Poly Medicure Ltd.

FundsIndia

Poly Medicure Ltd. has an average target of 3016.00 from 1 broker.

Poly Medicure Ltd.

25 Jul 2024

1768.10

1.47%

Fresh capacity and exports to drive momentum

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (PolyMed) Q1FY25 performance was boosted by exports (~23% YoY) while domestic business growth (~12% YoY) took a pause on high base. The company has commissioned four new plants that may double its device manufacturing capacity to 1.8bn units p.a by FY25 end.

Poly Medicure has lost -22.08% in the last 6 Months

Poly Medicure Ltd.

09 Aug 2023

1768.10

1.47%

Strong all-round performance

Hold: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure reported its all-time high revenues and EBITDA in Q1FY24 driven by solid performance across India (30% YoY growth) and Europe (35%). Softening of raw material prices fuelled a 220bps jump in gross margin. Ahead EBITDA margin is likely to be between 25-27%. Company will commercialise 4 manufacturing facilities in FY24 and launch 10-12 products in critical care segment, which will also likely drive growth and aid margin expansion.

Poly Medicure has lost -22.08% in the last 6 Months

Poly Medicure Ltd.

30 Jan 2023

1768.10

1.47%

Growth sustains; margin expands

Accumulate: Poly Medicure Ltd.

Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q3FY23 performance beats our estimates on all fronts. Revenue grew 23.7% YoY to Rs2.8bn (I-Sec: Rs2.7bn) led by strong demand across segments. EBITDA margin improved 270bps YoY and 140bps QoQ to 24.9%, supported by strong gross margin expansion.

Poly Medicure has lost -34.02% in the last 1 Year

Poly Medicure Ltd.

08 Nov 2022

1768.10

1.47%

Strong print

Hold: Poly Medicure Ltd.

Recommendation Target

ICICI Securities Limited

Poly Medicure’s (Polymed) Q2FY23 performance beats our estimates on all fronts.
Revenue grew 23.0% YoY to Rs2.7bn (I-Sec: Rs2.6bn) led by strong demand across segments.